Furthermore, the presence of TNFRSF9+ Tregs correlates with the composition of tumor-infiltrating lymphocytes and their ability to recognize antigens, marking them as valuable biomarkers for predicting responses to immune checkpoint inhibitors in melanoma patients [44]. The gene discussed is TNFRSF9; the disease is neoplasm.